201 related articles for article (PubMed ID: 16780018)
1. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
Wang L; Vuolo M; Suhrland MJ; Schlesinger K
Acta Cytol; 2006; 50(3):257-62. PubMed ID: 16780018
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology.
Saad RS; Luckasevic TM; Noga CM; Johnson DR; Silverman JF; Liu YL
Diagn Cytopathol; 2004 Jan; 30(1):1-6. PubMed ID: 14696137
[TBL] [Abstract][Full Text] [Related]
3. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.
Karabork A; Kaygusuz G; Ekinci C
Pathol Res Pract; 2010 Aug; 206(8):572-7. PubMed ID: 20400233
[TBL] [Abstract][Full Text] [Related]
4. Utility of polyclonal and monoclonal antibodies against carcinoembryonic antigen in hepatic fine-needle aspirates.
Rishi M; Kovatich A; Ehya H
Diagn Cytopathol; 1994 Dec; 11(4):358-61; discussion 361-2. PubMed ID: 7895575
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
Lau SK; Prakash S; Geller SA; Alsabeh R
Hum Pathol; 2002 Dec; 33(12):1175-81. PubMed ID: 12514785
[TBL] [Abstract][Full Text] [Related]
6. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.
Morrison C; Marsh W; Frankel WL
Mod Pathol; 2002 Dec; 15(12):1279-87. PubMed ID: 12481008
[TBL] [Abstract][Full Text] [Related]
7. Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: the utility of immunocytochemical panel.
Saleh HA; Aulicino M; Zaidi SY; Khan AZ; Masood S
Diagn Cytopathol; 2009 Mar; 37(3):184-90. PubMed ID: 19170172
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunohistochemical study of primary and metastatic carcinomas of the liver.
Ma CK; Zarbo RJ; Frierson HF; Lee MW
Am J Clin Pathol; 1993 May; 99(5):551-7. PubMed ID: 7684185
[TBL] [Abstract][Full Text] [Related]
9. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material.
Al-Muhannadi N; Ansari N; Brahmi U; Satir AA
Ann Hepatol; 2011; 10(4):508-15. PubMed ID: 21911893
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
Lin F; Abdallah H; Meschter S
Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
[TBL] [Abstract][Full Text] [Related]
11. Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma.
Röcken C; Licht J; Roessner A; Carl-McGrath S
J Clin Pathol; 2005 Oct; 58(10):1069-75. PubMed ID: 16189153
[TBL] [Abstract][Full Text] [Related]
12. Two-color immunostaining of liver fine needle aspiration biopsies with CD34 and carcinoembryonic antigen. Potential utilization in the diagnosis of primary hepatocellular carcinoma vs. metastatic tumor.
Yoder M; Zimmerman RL; Bibbo M
Anal Quant Cytol Histol; 2004 Apr; 26(2):61-4. PubMed ID: 15131892
[TBL] [Abstract][Full Text] [Related]
13. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
[TBL] [Abstract][Full Text] [Related]
14. Liver Metastases of Neuroendocrine Tumors Rarely Show Overlapping Immunoprofile with Hepatocellular Carcinomas.
Jin M; Zhou X; Yearsley M; Frankel WL
Endocr Pathol; 2016 Sep; 27(3):253-8. PubMed ID: 27300354
[TBL] [Abstract][Full Text] [Related]
15. pCEA canalicular immunostaining in fine needle aspiration biopsy diagnosis of hepatocellular carcinoma.
Wee A; Nilsson B
Acta Cytol; 1997; 41(4):1147-55. PubMed ID: 9250313
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
Chu PG; Ishizawa S; Wu E; Weiss LM
Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples.
Siddiqui MT; Saboorian MH; Gokaslan ST; Ashfaq R
Cancer; 2002 Feb; 96(1):49-52. PubMed ID: 11836703
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of CD10 immunohistochemical staining on cellblock in differentiating hepatocellular carcinoma from secondary malignancies of liver.
Singha J; Khan K; Chatterjee S
Indian J Pathol Microbiol; 2018; 61(4):510-515. PubMed ID: 30303139
[TBL] [Abstract][Full Text] [Related]
19. MOC-31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma.
Niemann TH; Hughes JH; De Young BR
Cancer; 1999 Oct; 87(5):295-8. PubMed ID: 10536355
[TBL] [Abstract][Full Text] [Related]
20. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas.
Borscheri N; Roessner A; Röcken C
Am J Surg Pathol; 2001 Oct; 25(10):1297-303. PubMed ID: 11688465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
